THE HALFAX HEIMDALL AUGUR

FDA panel considers a first-of-its-kind flu vaccine using mRNA technology A sign marks an entrance to a Moderna building in Cambridge, Mass., May 18, 2020. (AP Photo/Bill Sikes, File)prnto WASHINGTON (AP) — U.S. health advisers are debating a new kind offlu vaccineThursday, the first made with the samemRNA technologythat was key to ending the COVID-19 pandemic. Moderna is seeking Food and Drug Administration approval ofits new shot, dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season. Tens of thousands of Americans die from influenza every year, and older adults are among the most vulnerable. There are various types of flu vaccines already available in the U.S., including three specifically recommended for people 65 and older. But vaccines made with theNobel Prize-winning mRNA technologyare faster to manufacture than other types — something experts say might help if the shape-shifting flu virus mutates in a way that requires suddenly brewing new doses to match. In a study of 40,000 people age 50 and older, Moderna’s mRNA vaccine reduced flu cases by about 27% compared to thos…

FDA panel considers a first-of-its-kind flu vaccine using mRNA technology <p>Moderna seeks FDA approval of its new shot, mFlusvia, as option for 50 and older</p><p>US health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic.</p><p>Moderna is seeking Food and Drug Administration (FDA) approval of its new shot , dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season.</p> <a href="https://www.theguardian.com/us-news/2026/jun/18/fda-flu-vaccine-mrna">Continue reading...</a>

🚨 An FDA advisory committee has recommended approval of Moderna’s mRNA flu vaccine for adults 65 and older. The vaccine could become the first mRNA-based influenza shot in the U.S., pending final FDA approval later this year. #FluVaccine #mRNA #FDA

FDA panel backs first-of-its-kind flu vaccine using mRNA technology Lifestyle Health and Fitness Actions Facebook Tweet Email FDA panel backs first-of-its-kind flu vaccine using mRNA technology Prev Next Bill Sikes/AP A sign marks an entrance to a Moderna building in Cambridge, Mass. By: By LAURAN NEERGAARD and MATTHEW PERRONE Posted and last updated WASHINGTON (AP) — A new kind of flu vaccine moved a step closer to the U.S. market Thursday as federal health advisers recommended approval of the first made with the same mRNA technology that was key to ending the COVID-19 pandemic. The Food and Drug Administration is evaluating Moderna's new shot , dubbed mFlusiva, for older Americans ahead of the winter flu season. Moderna is seeking full approval for the vaccine's use in people ages 50 to 64 — along with authorization for use in those 65 and older while it conducts additional testing. The FDA's independent advisory committee evaluated Moderna's studies of the vaccine and voted unanimously that its benefits appear to outweigh any risks for both age groups. The FDA will consider that recommendation in making a final decision by early August. Tens of thousands of Americans die from i…

FDA panel considers a first-of-its-kind flu vaccine using mRNA technology FILE - A sign marks an entrance to a Moderna building in Cambridge, Mass., May 18, 2020.prnto Bill Sikes/AP Photo/Bill Sikes WASHINGTON (AP) — U.S. health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic. Moderna is seeking Food and Drug Administration approval of its new shot, dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season. Advertisement Article continues below this ad Tens of thousands of Americans die from influenza every year, and older adults are among the most vulnerable. There are various types of flu vaccines already available in the U.S., including three specifically recommended for people 65 and older. But vaccines made with the Nobel Prize-winning mRNA technology are faster to manufacture than other types — something experts say might help if the shape-shifting flu virus mutates in a way that requires suddenly brewing new doses to match. More Business Once CT's consumer crusader, utility's newe…

FDA panel considers a first-of-its-kind flu vaccine using mRNA technology <p>WASHINGTON &#8212; U.S. health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic.</p>

FDA Advisory Panel Votes Today on First mRNA Flu Vaccine as MFLUSIVA ... Justin Sullivan | Getty Images Share on Twitter Share on Facebook Share on Pocket It has been more than three years since Moderna's mRNA technology proved it could protect against a respiratory virus in the real world. Today, that platform faces a new and historic test: the first-ever FDA advisory committee vote on an mRNA-based seasonal influenza vaccine. The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) convened June 18, 2026, to assess the benefit-risk profile of MFLUSIVA (mRNA-1010) , Moderna's investigational trivalent mRNA seasonal influenza vaccine, with the FDA's formal decision date set for August 5, 2026. The pre-meeting briefing documents released June 16 showed no "major deficiencies," triggering a 9% stock surge and setting up what may be a landmark moment in vaccine history. What MFLUSIVA Is — and What the Phase 3 Trial Showed MFLUSIVA (formerly mRNA-1010) is an mRNA-based trivalent influenza vaccine containing antigens against four influenza strains: H1N1, H3N2, B/Yamagata (included for formulation stability), and B/Victoria. It is manufactured by Moderna TX Inc. an…

FDA panel considers first-of-its-kind flu vaccine using mRNA technology FDA panel considers first-of-its-kind flu vaccine using mRNA technology BY Associated Press Nationwide PUBLISHED 8:02 AM ET Jun. 18, 2026 PUBLISHED June 18, 2026 @8:02 AM SHARE WASHINGTON — U.S. health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic. What You Need To Know U.S. health advisers are debating a new kind of flu vaccine The new shot is made with the same mRNA technology that was key to ending the COVID-19 pandemic Moderna is seeking Food and Drug Administration approval for mFlusiva as an option for people 50 and older The FDA advisory panel is meeting Thursday to consider it Moderna is seeking Food and Drug Administration approval of its new shot, dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season. Tens of thousands of Americans die from influenza every year, and older adults are among the most vulnerable. There are various types of flu vaccines already available in the U.S., including three specif…

FDA panel considers first-of-its-kind flu shot using mRNA technology FILE – A sign marks an entrance to a Moderna building in Cambridge, Mass., May 18, 2020. (AP Photo/Bill Sikes, File)prnto By Associated Press PUBLISHED: June 18, 2026 at 7:27 AM EDT | UPDATED: June 18, 2026 at 7:30 AM EDT Getting your Trinity Audio player ready... By LAURAN NEERGAARD and MATTHEW PERRONE WASHINGTON (AP) — U.S. health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic. Moderna is seeking Food and Drug Administration approval of its new shot , dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season. Tens of thousands of Americans die from influenza every year, and older adults are among the most vulnerable. There are various types of flu vaccines already available in the U.S., including three specifically recommended for people 65 and older. But vaccines made with the Nobel Prize-winning mRNA technology are faster to manufacture than other types — something experts say might help if the shape-shifting flu v…

FDA panel considers a first-of-its-kind flu vaccine using mRNA technology FDA panel considers a first-of-its-kind flu vaccine using mRNA technology WASHINGTON (AP) — U.S. health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic. Posted 6/18/2026, 11:13:13 AM Related Associated Press AP Health AP Business AP U.S. news AP Science FILE - A sign marks an entrance to a Moderna building in Cambridge, Mass., May 18, 2020. (AP Photo/Bill Sikes, File)prnto By LAURAN NEERGAARD and MATTHEW PERRONE — Associated Press WASHINGTON (AP) — U.S. health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic. Moderna is seeking Food and Drug Administration approval of its new shot, dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season. Other WRAL Top Stories Tens of thousands of Americans die from influenza every year, and older adults are among the most vulnerable. There are various types of flu vaccines already …

Moderna's mRNA flu vaccine backed by FDA advisers Moderna's mRNA flu vaccine backed by FDA advisers Sign up now: Get ST's newsletters delivered to your inbox The nine panel members voted unanimously in favour of use of Moderna’s shot mFlusiva in adults aged 50 to 64. PHOTO: REUTERS Published Jun 19, 2026, 04:35 AM Updated Jun 19, 2026, 04:35 AM MASSACHUSETTS - Advisers to the US Food and Drug Administration on June 18 backed approval of Moderna’s flu vaccine for adults aged 50 and older, saying its benefits outweigh the risks, boosting the company’s chances of launching the first mRNA-based seasonal flu shot. The nine panel members voted unanimously in favour of use of Moderna’s shot mFlusiva in adults aged 50 to 64, as well as for those 65 and older, which has faced additional regulatory hurdles. The FDA’s Vaccines and Related Biological Products Advisory Committee meeting was seen as a test of whether the agency is reverting to its longstanding approach to vaccine reviews after recent leadership turnover. Under former FDA Commissioner Marty Makary and his lieutenants, the FDA had rejected Moderna’s initial application for the shot, before reversing course. The advisers on June 1…

FDA panel considers a first-of-its-kind flu vaccine using mRNA ... U.S. health advisers are debating a new kind of flu vaccine WASHINGTON --U.S. health advisers are debating a new kind offlu vaccineThursday, the first made with the samemRNA technologythat was key to ending the COVID-19 pandemic. Moderna is seeking Food and Drug Administration approval ofits new shot, dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season. Tens of thousands of Americans die from influenza every year, and older adults are among the most vulnerable. There are various types of flu vaccines already available in the U.S., including three specifically recommended for people 65 and older. But vaccines made with theNobel Prize-winning mRNA technologyare faster to manufacture than other types — something experts say might help if the shape-shifting flu virus mutates in a way that requires suddenly brewing new doses to match. In a study of 40,000 people age 50 and older, Moderna’s mRNA vaccine reduced flu cases by about 27% compared to those given another routinely used vaccine brand. Ahead of the meeting,…

FDA panel considers first-of-its-kind flu vaccine using mRNA technology <p>U.S. health advisers are debating a new kind of flu vaccine, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic.</p>

FDA panel backs first-of-its-kind flu vaccine using mRNA technology WASHINGTON (AP) — A new kind offlu vaccinemoved a step closer to the U.S. market Thursday as federal health advisers recommended approval of the first made with the samemRNA technologythat was key to ending the COVID-19 pandemic. The Food and Drug Administration is evaluating Moderna’snew shot, dubbed mFlusiva, for older Americans ahead of the winter flu season. Moderna is seeking full approval for the vaccine’s use in people ages 50 to 64 — along with authorization for use in those 65 and older while it conducts additional testing. The FDA’s independent advisory committee evaluated Moderna’s studies of the vaccine and voted unanimously that its benefits appear to outweigh any risks for both age groups. The FDA will consider that recommendation in making a final decision by early August. Tens of thousands of Americans die from influenza every year, and older adults are among the most vulnerable. There are various types offlu vaccinesalready available in the U.S., including three specifically recommended for people 65 and older. But vaccines made with theNobel Prize-winning mRNA technologyare faster to manufactu…

New Flu Vaccine WASHINGTON (AP) — U.S. health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic. Moderna is seeking Food and Drug Administration approval of its new shot, dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season. Tens of thousands of Americans die from influenza every year, and older adults are among the most vulnerable. There are various types of flu vaccines already available in the U.S., including three specifically recommended for people 65 and older. But vaccines made with the Nobel Prize-winning mRNA technology are faster to manufacture than other types — something experts say might help if the shape-shifting flu virus mutates in a way that requires suddenly brewing new doses to match. In a study of 40,000 people age 50 and older, Moderna’s mRNA vaccine reduced flu cases by about 27% compared to those given another routinely used vaccine brand. Ahead of the meeting, FDA published a favorable review of that data and reported no safety concerns. Moderna is seeking …

FDA advisors unanimously vote to approve Moderna's mRNA after agency ... Text settings Story text Size Small Standard Large Width * Standard Wide Links Standard Orange * Subscribers only Learn more Minimize to nav Independent advisors for the Food and Drug Administration on Friday voted 9–0 in support of approving Moderna’s seasonal mRNA flu vaccine, which a Trump appointee at the agency initially tried to block from even being reviewed. In an all-day meeting, members of the FDA’s advisory committee—known as VRBPAC for Vaccines and Related Biological Products Advisory Committee—pored over data and presentations on the vaccine, which is dubbed mRNA-1010 and branded as mFlusiva. The presentations included a review from FDA scientists, which was supportive of the vaccine. Data from a Phase 3 trial including over 40,000 adults age 50 and older found the mRNA vaccine was around 27 percent more effective against seasonal flu than a standard flu shot. A smaller Phase 3 trial, involving data from nearly 3,000 people age 65 years and older, showed the shot produces stronger immune responses than a high-dose flu vaccine, which is recommended for this age group. The safety profile of…